146 related articles for article (PubMed ID: 23209663)
1. Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis.
Lee CC; Ho HC; Hsiao SH; Huang TT; Lin HY; Li SC; Chou P; Su YC
PLoS One; 2012; 7(11):e50163. PubMed ID: 23209663
[TBL] [Abstract][Full Text] [Related]
2. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.
Bhola NE; Thomas SM; Freilino M; Joyce S; Sahu A; Maxwell J; Argiris A; Seethala R; Grandis JR
Clin Cancer Res; 2011 Aug; 17(15):4996-5004. PubMed ID: 21653688
[TBL] [Abstract][Full Text] [Related]
3. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era.
Marín M; Gudiol C; Castet F; Oliva M; Peiró I; Royo-Cebrecos C; Carratalà J; Mesia R
Clin Transl Oncol; 2019 Feb; 21(2):187-196. PubMed ID: 29948973
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.
Chan AL; Leung HW; Huang SF
Clin Drug Investig; 2011 Oct; 31(10):717-26. PubMed ID: 21744880
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
8. A descriptive epidemiological study on the treatment options for head and neck cancer: Transition before and after approval of cetuximab.
Yamada S; Sato I; Kawakami K
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):330-336. PubMed ID: 30467909
[TBL] [Abstract][Full Text] [Related]
9. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.
Srivastava RM; Trivedi S; Concha-Benavente F; Hyun-Bae J; Wang L; Seethala RR; Branstetter BF; Ferrone S; Ferris RL
Cancer Immunol Res; 2015 Aug; 3(8):936-45. PubMed ID: 25972070
[TBL] [Abstract][Full Text] [Related]
10. Suicide attempts in patients with head and neck cancer in Taiwan.
Sun LM; Lin CL; Shen WC; Kao CH
Psychooncology; 2020 Jun; 29(6):1026-1035. PubMed ID: 32128937
[TBL] [Abstract][Full Text] [Related]
11. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
12. Increase in stroke risk in patients with head and neck cancer: a retrospective cohort study.
Chu CN; Chen SW; Bai LY; Mou CH; Hsu CY; Sung FC
Br J Cancer; 2011 Oct; 105(9):1419-23. PubMed ID: 21915128
[TBL] [Abstract][Full Text] [Related]
13. Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.
Aggarwal H; Punekar RS; Li L; Carter GC; Walker MS
Health Qual Life Outcomes; 2020 Jun; 18(1):195. PubMed ID: 32571349
[TBL] [Abstract][Full Text] [Related]
14. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
Wheeler S; Siwak DR; Chai R; LaValle C; Seethala RR; Wang L; Cieply K; Sherer C; Joy C; Mills GB; Argiris A; Siegfried JM; Grandis JR; Egloff AM
Clin Cancer Res; 2012 Apr; 18(8):2278-89. PubMed ID: 22351687
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
Li JZ; Zheng JW; Zhang ZY
Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
17. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
Argiris A; Heron DE; Smith RP; Kim S; Gibson MK; Lai SY; Branstetter BF; Posluszny DM; Wang L; Seethala RR; Dacic S; Gooding W; Grandis JR; Johnson JT; Ferris RL
J Clin Oncol; 2010 Dec; 28(36):5294-300. PubMed ID: 21079141
[TBL] [Abstract][Full Text] [Related]
18. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.
Schmitz S; Hamoir M; Reychler H; Magremanne M; Weynand B; Lhommel R; Hanin FX; Duprez T; Michoux N; Rommel D; Lonneux M; Cappoen N; Gillain A; Machiels JP
Ann Oncol; 2013 Sep; 24(9):2261-6. PubMed ID: 23704200
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
20. Suicide risk after head and neck cancer diagnosis in Taiwan: A retrospective cohort study.
Liu FH; Huang JY; Lin C; Kuo TJ
J Affect Disord; 2023 Jan; 320():610-615. PubMed ID: 36198362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
